Dysfunctional fat cells, lipotoxicity and type 2 diabetes

Area of Science:

• Endocrinology
• Metabolic Syndrome
• Adipose Tissue Biology

Background:

• Type 2 diabetes involves insulin resistance and impaired insulin secretion.
• Adipocyte dysfunction, including enlarged fat cells and altered metabolism, is central to type 2 diabetes pathogenesis.
• Enlarged adipocytes exhibit insulin resistance, leading to elevated free fatty acids (FFA) and lipotoxicity.

Purpose of the Study:

• To examine the role of adipose tissue in type 2 diabetes development.
• To highlight the therapeutic potential of Peroxisome-proliferator activated receptor gamma (PPARgamma) agonists in managing type 2 diabetes.

Main Methods:

• Review of existing evidence on adipose tissue dysfunction in type 2 diabetes.
• Analysis of the mechanisms by which enlarged adipocytes contribute to insulin resistance and impaired insulin secretion.
• Evaluation of the effects of PPARgamma agonists on adipose tissue metabolism and insulin sensitivity.

Main Results:

• Enlarged fat cells are resistant to insulin, causing elevated FFA levels and lipotoxicity.
• Dysfunctional adipocytes produce pro-inflammatory cytokines and reduce insulin-sensitizing cytokines.
• PPARgamma agonists redistribute fat, enhance adipocyte insulin sensitivity, inhibit lipolysis, and reduce FFA.

Conclusions:

• Adipose tissue plays a critical role in the pathogenesis of type 2 diabetes.
• Targeting adipose tissue, particularly with PPARgamma agonists, offers a promising therapeutic strategy for type 2 diabetes.
• PPARgamma agonists improve metabolic parameters by modulating adipocyte function and fat distribution.